<DOC>
	<DOCNO>NCT00581919</DOCNO>
	<brief_summary>Patients receive Bortezomib , Dexamethasone , Doxorubicin 21 day cycle total 4 8 time ( base response treatment ) . Patients also receive acetyl-L-carnitine ( ALCAR ) daily .</brief_summary>
	<brief_title>Ph 2 Bortezomib , Dexamethasone , + Doxorubicin With ALCAR Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>The primary objective study ass overall response rate treatment . Secondary objective include : evaluate describe incidence chemotherapy-induced peripheral neuropathy use FACT/GOG-Ntx assessment tool ; evaluate utility add ALCAR chemotherapy reduce incidence peripheral neuropathy ; evaluate utility Grooved Pegboard Completion Time longitudinal measure peripheral neuropathy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>Patients previously treat multiple myeloma measurable serum urine monoclonal protein . Patients previous doxorubicin treatment total 220 mg/m2 LVEF le 45 % Patients &gt; grade II sensory neuropathy baseline assess PI exclude No history seizure ALCAR may lower seizure threshold Known HIV infection Current pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>previously treat multiple myeloma</keyword>
</DOC>